South Korea’s Drug Pricing Reforms Spark Industry Concerns

South Korea is poised to revise its drug pricing system for the first time in 13 years, aiming to lower costs for patients and improve access to medication. However, the move is facing strong opposition from the pharmaceutical and biotech industry, which fears it will stifle innovation and investment in research and development (R&D). The proposed changes center on reducing the price calculation rate for generic drugs and implementing more flexible contracts for innovative treatments.

Government Rationale for Price Cuts

The Ministry of Health and Welfare announced plans to lower the price calculation rate for generic drugs from 53.55% to the 40% range of the original drug price as reported by The Korea Times. This aims to address concerns that generic drug prices in South Korea are higher than in other countries. The government anticipates savings of approximately 250 billion Korean won per year, or 1 trillion won over four years, which will be reinvested in essential medicines and new drug development .

Industry Concerns and Potential Impact

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) has voiced strong concerns, arguing that price cuts will significantly reduce sales and hinder R&D investment. The industry estimates potential sales losses of 3.6 trillion Korean won annually as reported by The Chosun Ilbo. Industry leaders warn that this could lead to a decline in investment, threats to the production of essential medicines and job losses .

Addressing the Decline of Public Health Doctors

Concurrently, South Korea is addressing a growing shortage of public health doctors, particularly in rural areas. The government plans to leverage telemedicine and digital technology to provide healthcare access to underserved communities. Specifically, residents in areas without physicians will be able to receive remote consultations with doctors facilitated by nurses at local health centers, with medications delivered via courier as reported by Daily Pharm. This initiative aims to mitigate the impact of a 44% decrease in doctors at regional healthcare facilities over the past decade, with the number of new entrants expected to fall below 100 in 2026 .

Flexible Pricing and Rare Disease Treatments

To encourage the introduction of innovative pharmaceuticals, the government is also introducing a “flexible drug price contract” system. This will allow the National Health Insurance Service and pharmaceutical companies to negotiate separate contracts, potentially expediting access to treatments for rare diseases and maintaining competitiveness in overseas markets . The government aims to shorten the reimbursement listing period for rare disease treatments to within 100 days, down from a current maximum of 240 days .

The Future of South Korea’s Pharmaceutical Industry

The reforms highlight a tension between controlling healthcare costs and fostering innovation within South Korea’s pharmaceutical industry. Experts emphasize the need for a balanced approach that supports both affordability and continued investment in R&D as noted by Korea BioMed. Improving the valuation of new drugs and increasing the self-sufficiency rate of active pharmaceutical ingredients (APIs) are also seen as crucial steps towards establishing South Korea as a global pharmaceutical hub .